journal article·2021-12-08

Engineered Nanovaccine Targeting Clec9a+ Dendritic Cells Remarkably Enhances the Cancer Immunotherapy Effects of STING Agonist

Shanshan Gou, Wenwen Liu, Shuai Wang, Guanyu Chen, Zhenzhen Chen, Lu Qiu, Xiuman Zhou, Yahong Wu, Yuanming Qi, Yanfeng Gao

Nano Letters· Volume 21· Issue 23
Publisher page

Abstract

Agonists of the stimulator of interferon gene (STING) are considered as promising therapeutics for cancer immunotherapy. However, drug-delivery barriers and adverse effects limit the clinical application of STING agonists. Therefore, it is an urgent need to develop an ideal delivery system to deliver STING agonists and avoid side effects. Here, we discovered that STING agonists significantly stimulated type I interferon (IFN) secretion in Clec9a+ dendritic cells (DCs). Then, we designed an engineered peptide-expressed biomimetic cancer cell membrane (EPBM)-coated nanovaccine drug-delivery system (PLGA/STING@EPBM) to deliver STING agonists and tumor antigens to Clec9a+ DCs. The PLGA/STING@EPBM nanovaccine significantly enhanced IFN-stimulated expression of genes and antigen cross-presentation of Clec9a+ DCs, thus eliciting strong antitumor effects in both anti-PD-1-responsive and -resistant tumor models without obvious cytotoxicity. Moreover, the PLGA/STING@EPBM nanovaccine combined with radiotherapy exhibited remarkable synergistic antitumor effects. Our work highlights the great potential of a EPBM-coated nanovaccine for systemic STING agonist delivery as an attractive tool for cancer immunotherapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: interferon and immune responses · Immunotherapy and Immune Responses · Virus-based gene therapy research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China

School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen 518107, China

Henan Key Laboratory of Bioactive Macromolecules, Zhengzhou University, Zhengzhou 450001, China

International Joint Laboratory for Protein and Peptide Drugs of Henan Province, Zhengzhou University, Zhengzhou 450001, China

Funding

National Natural Science Foundation of China · Guangdong Province · Shenzhen Science and Technology Program

References (56)

Show source-provided references
1. 10.1038/s41568-019-0186-910.1038/s41568-019-0186-9 ↗
2. 10.1039/C8CS00896E10.1039/C8CS00896E ↗
3. 10.1016/j.addr.2019.05.00710.1016/j.addr.2019.05.007 ↗
4. 10.1158/2326-6066.CIR-18-027710.1158/2326-6066.CIR-18-0277 ↗
5. 10.1126/science.abc662210.1126/science.abc6622 ↗
6. 10.1186/s13045-020-00862-w10.1186/s13045-020-00862-w ↗
7. 10.1002/adfm.20190662310.1002/adfm.201906623 ↗
8. 10.1016/j.drudis.2019.11.00710.1016/j.drudis.2019.11.007 ↗
9. 10.1186/s12943-019-1087-y10.1186/s12943-019-1087-y ↗
10. 10.1038/s41422-020-00395-410.1038/s41422-020-00395-4 ↗
11. 10.1172/JCI8689210.1172/JCI86892 ↗
12. 10.1186/s40425-018-0422-y10.1186/s40425-018-0422-y ↗
13. 10.1111/imr.1276510.1111/imr.12765 ↗
14. 10.1038/s41586-018-0705-y10.1038/s41586-018-0705-y ↗
15. 10.1038/s41565-018-0342-510.1038/s41565-018-0342-5 ↗
16. 10.1002/adbi.20160001310.1002/adbi.201600013 ↗
17. 10.1126/science.aba609810.1126/science.aba6098 ↗
18. 10.1126/science.abb425510.1126/science.abb4255 ↗
19. 10.1016/j.biomaterials.2020.12054210.1016/j.biomaterials.2020.120542 ↗
20. 10.1136/jitc-2019-00028210.1136/jitc-2019-000282 ↗
21. 10.1146/annurev-immunol-020711-07495010.1146/annurev-immunol-020711-074950 ↗
22. 10.1016/j.immuni.2012.04.01210.1016/j.immuni.2012.04.012 ↗
23. 10.1172/JCI3458410.1172/JCI34584 ↗
24. 10.7150/thno.5640610.7150/thno.56406 ↗
25. 10.1021/acsnano.5b0104210.1021/acsnano.5b01042 ↗
26. 10.1126/science.aau081010.1126/science.aau0810 ↗
27. 10.1126/scitranslmed.aav852110.1126/scitranslmed.aav8521 ↗
28. 10.1021/acs.nanolett.0c0398210.1021/acs.nanolett.0c03982 ↗
29. 10.1021/acsnano.0c0377610.1021/acsnano.0c03776 ↗
30. 10.18632/oncotarget.962410.18632/oncotarget.9624 ↗
31. 10.1016/j.immuni.2019.10.00910.1016/j.immuni.2019.10.009 ↗
32. 10.1158/0008-5472.CAN-15-188510.1158/0008-5472.CAN-15-1885 ↗
33. 10.1016/j.bbrc.2005.01.09310.1016/j.bbrc.2005.01.093 ↗
34. 10.1038/srep1904910.1038/srep19049 ↗
35. 10.1186/s40425-019-0654-510.1186/s40425-019-0654-5 ↗
36. 10.1016/S1470-2045(20)30271-010.1016/S1470-2045(20)30271-0 ↗
37. 10.1016/j.ccell.2016.02.00410.1016/j.ccell.2016.02.004 ↗
38. 10.1002/anie.20200278310.1002/anie.202002783 ↗
39. 10.1038/nnano.2017.5210.1038/nnano.2017.52 ↗
40. 10.4049/jimmunol.180.5.313210.4049/jimmunol.180.5.3132 ↗
41. 10.1186/s13045-019-0721-x10.1186/s13045-019-0721-x ↗
42. 10.1038/s41551-020-00675-910.1038/s41551-020-00675-9 ↗
43. 10.1038/nmat377510.1038/nmat3775 ↗
44. 10.1126/scitranslmed.300376310.1126/scitranslmed.3003763 ↗
45. 10.3389/fbioe.2020.0094310.3389/fbioe.2020.00943 ↗
46. 10.1158/2159-8290.CD-19-076110.1158/2159-8290.CD-19-0761 ↗
47. 10.7150/thno.3757410.7150/thno.37574 ↗
48. 10.1016/j.apsb.2017.11.00910.1016/j.apsb.2017.11.009 ↗
49. 10.1021/acsnano.7b0904110.1021/acsnano.7b09041 ↗
50. 10.1002/adma.20180717510.1002/adma.201807175 ↗
51. 10.3389/fimmu.2018.0282110.3389/fimmu.2018.02821 ↗
52. 10.1002/anie.20150622510.1002/anie.201506225 ↗
53. 10.1136/jitc-2020-00090510.1136/jitc-2020-000905 ↗
54. 10.1016/j.apsb.2020.01.00510.1016/j.apsb.2020.01.005 ↗
55. 10.1182/blood-2009-02-20687010.1182/blood-2009-02-206870 ↗
56. 10.1038/nrc395810.1038/nrc3958 ↗